RYAN SANTIN: Open Payments
NPI 1649698523 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,270 in 77 payments from 17 companies in 2025. Trend: 2023 $115 · 2024 $651 · 2025 $1,270
Food & beverage: $1,158Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $396 |
| E.R. Squibb & Sons, L.L.C. | 16 | $153 |
| Neurocrine BioSciences, Inc. | 7 | $113 |
| Alkermes, Inc. | 4 | $111 |
| VERTEX PHARMACEUTICALS INCORPORATED | 4 | $79 |
| Janssen Pharmaceuticals, Inc | 4 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $63 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Lundbeck LLC | 2 | $36 |
Products named: UZEDY, AUSTEDO XR, INGREZZA, COBENFY, REXULTI, ARISTADA, CAPLYTA, Qelbree.
Industry payments across NE — which companies pay providers there.
